Prospective Follow-up Study of the Aortic Diameter in Patients With Giant Cell Arteritis (ATACT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01588483|
Recruitment Status : Recruiting
First Posted : May 1, 2012
Last Update Posted : May 18, 2016
Giant cell arteritis (GCA) is the most frequent vasculitis in patients above 50 years of age. The disease has limited mortality, mostly due to the development of aortic aneurysms, leading to dissection and rupture. The probability to develop this complication is 17 x higher at the level of the thoracic aorta and 2,4 x at the level of the abdominal aorta in patients with GCA when compared with a control group. Therefore, follow-up of the aortic diameter in patients with GCA is part of good clinical practice. Previous retrospective research showed a link between FDG-uptake at the level of the thoracic aorta, on positron-emission-tomography (PET) at the time of diagnosis, and the increase of diameter and volume of the thoracic aorta during follow-up (on computed tomography (CT)).
The purpose of this prospective study is to follow-up on the aortic diameter, and to correlate these measures with FDG-PET uptake at diagnosis. Ideally, this would allow us to define a group of patients at high risk to develop an aortic aneurysm, already at the time of diagnosis.
|Condition or disease|
|Giant Cell Arteritis|
As standard care, all patients with a suspicion of GCA undergo a biopsy of the temporal artery and a PET scintigraphy to evaluate the presence of large vessel vasculitis. Patients with proven GCA on biopsy and/or scintigraphy undergo a computed tomography (CT) of the aorta without the administration of contrast, at diagnosis and yearly thereafter (every 12 +/- 3 months) for 10 years.
Measurements include the diameter of the ascending aorta, aortic arch, descending aorta, suprarenal, juxtarenal and infrarenal aorta, and the volume of the thoracic and the abdominal aorta. These measurements are correlated with FDG-uptake at the level of the aorta on PET-scintigraphy at the time of diagnosis. All patients will be treated according to accepted guidelines and standard care in our center (methylprednisolone started at 32 mg/day, with slowly declining doses until stop after 1 to 1,5 years of treatment).
|Study Type :||Observational|
|Estimated Enrollment :||150 participants|
|Official Title:||Prospective Study for the Follow-up of Aortic Diameter in Patients With Arteritis Temporalis / Giant Cell Arteritis.|
|Study Start Date :||March 2012|
|Estimated Primary Completion Date :||March 2022|
giant cell arteritis
patients with biopsy and/or scintigraphy proven GCA
- Diameter of aorta. [ Time Frame: yearly, until 10 years after diagnosis ]diameter of ascending aorta, arcus aortae, descending aorta, suprarenal, juxtarenal and infrarenal abdominal aorta
- Volume of aorta [ Time Frame: yearly, until 10 years after diagnosis ]volume of the thoracic and abdominal aorta
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01588483
|Contact: Daniël Blockmans, MD, PhD||daniël.firstname.lastname@example.org|
|Contact: Liesbet Henckaerts, MD, PhDemail@example.com|
|University Hospital Leuven||Recruiting|
|Leuven, Belgium, 3000|
|Contact: Daniël Blockmans, MD, PhD firstname.lastname@example.org|
|Contact: Liesbet Henckaerts, MD, PhD email@example.com|
|Principal Investigator: Daniël Blockmans, MD, PhD|
|Sub-Investigator: Liesbet Henckaerts, MD, PhD|
|Principal Investigator:||Daniël Blockmans, MD, PhD||University Hospital, Gasthuisberg|